Codexis Inks Deal With Pharmaceutical Firm To Manufacture siRNA Material

Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced it has entered into an agreement with an innovator pharmaceutical company to manufacture 50 grams of small interfering RNA (siRNA) using its proprietary ECO Synthesis manufacturing platform to support preclinical development of a therapeutic candidate targeting a cardiovascular indication.

Under the terms of the agreement, Codexis will produce siRNA material to support its partner's preclinical program. The engagement represents an important demonstration of the platform's ability to deliver meaningful quantities of RNA material beyond early research volumes and establishes a potential pathway to further scale-up and manufacturing, subject to program advancement.